Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions

Nora Franzen, Giorgia Romagnoli, Andreas Ziegler, Valesca P Retèl, Theo J S Offerman, Wim H van Harten*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)

Abstract

The high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet, there are promising policy proposals aimed at improving affordability without compromising innovation. In seeking new policy solutions, we argue for a shift away from entrenched opinion toward an evidence-based discourse that is grounded in experiments and real-world pilot studies. We offer a novel perspective and practical recommendations on how empirical evidence could and should be gathered to inform evidence-based policy interventions that lead to sustainable medicine prices in oncology.See related article by Franzen et al. (Cancer Res Commun 2022;2:39-47).

Original languageEnglish
Pages (from-to)299-302
Number of pages4
JournalCancer Discovery
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Feb 2022

Bibliographical note

©2022 American Association for Cancer Research.

Fingerprint

Dive into the research topics of 'Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions'. Together they form a unique fingerprint.

Cite this